Finance

Lists
PTGX:NASDAQ
Protagonist Therapeutics Inc
139,91 US$
-0,72%
(-1,01) 1D
139,91 US$
0,00% (0,00)
After hours
Closed: 8 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTGX...
Open
139,57 US$
High
142,18 US$
Low
137,99 US$
Mkt. cap
9,05 მლრდ.
Avg. vol.
692,74 ათ.
Volume
1,00 მლნ.
P/E ratio
134,90
52-wk high
160,81 US$
52-wk low
65,56 US$
EPS
1,04 US$
Beta
1,53
Shares outstanding
64,71 მლნ.
No. of employees
141
Open
139,57 US$
High
142,18 US$
Low
137,99 US$
Mkt. cap
9,05 მლრდ.
Avg. vol.
692,74 ათ.
Volume
1,00 მლნ.
P/E ratio
134,90
52-wk high
160,81 US$
52-wk low
65,56 US$
EPS
1,04 US$
Beta
1,53
Shares outstanding
64,71 მლნ.
No. of employees
141
News stories
From web sources and news partners
About Protagonist Therapeutics Inc
CEO-
Employees141
Founded2006
HeadquartersNewark, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to PTGX in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PTGX in the last 3 months.
Highest
Current 139,91 US$
186,00 US$ (+32,94%)
Average
167,00 US$ (+19,36%)
Lowest
121,00 US$ (-13,52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
182,00 US$
+30,1%
09/09/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
186,00 US$
+32,9%
08/31/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
149,00 US$
+6,5%
08/31/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
09/01/2026
Etzer Darout
Barclays
Buy
Maintained
180,00 US$
+28,7%
08/31/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
173,00 US$
+23,7%
08/31/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
170,00 US$
+21,5%
08/31/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
170,00 US$
+21,5%
09/01/2026
Evan Seigerman
BMO Capital
Buy
Maintained
178,00 US$
+27,2%
08/30/2026
Yun Zhong
Wedbush
Buy
Maintained
173,00 US$
+23,7%
08/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
155,00 US$
+10,8%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
121,00 US$
-13,5%
07/16/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
110,00 US$
-21,4%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
4,71 მლნ.
7,44 მლნ.
56,37 მლნ.
213,48 მლნ.
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40,00 მლნ.
46,36 მლნ.
46,74 მლნ.
42,06 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,13 მლნ.
11,43 მლნ.
13,28 მლნ.
12,65 მლნ.
Operating expense
51,13 მლნ.
57,79 მლნ.
60,02 მლნ.
54,71 მლნ.
Total operating expenses
51,13 მლნ.
57,79 მლნ.
60,02 მლნ.
54,71 მლნ.
Operating income
-46,42 მლნ.
-50,36 მლნ.
-3,65 მლნ.
158,77 მლნ.
Other non operating income
-
27,00 ათ.
53,00 ათ.
-81,00 ათ.
EBT including unusual items
-39,34 მლნ.
-43,72 მლნ.
2,28 მლნ.
165,11 მლნ.
EBT excluding unusual items
-39,34 მლნ.
-43,72 მლნ.
2,28 მლნ.
165,11 მლნ.
Income tax expense
-
666,00 ათ.
-1,50 მლნ.
2,26 მლნ.
Effective tax rate
-
-1,52%
-65,85%
1,37%
Other operating expenses
-
-
-
-
Net income
-39,34 მლნ.
-44,38 მლნ.
3,78 მლნ.
162,85 მლნ.
Net profit margin
-834,87%
-596,80%
6,71%
76,28%
Earnings per share
-0,62
-0,69
0,05
2,29
Interest and investment income
7,05 მლნ.
6,76 მლნ.
5,88 მლნ.
6,43 მლნ.
Interest expense
-
-
-
-
Net interest expenses
7,05 მლნ.
6,76 მლნ.
5,88 მლნ.
6,43 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-46,06 მლნ.
-49,98 მლნ.
-3,24 მლნ.
159,16 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები